Management of Hepatitis B in Liver Transplantation Patients

The success of orthotopic liver transplantation for patients with hepatitis B virus (HBV) disease has been compromised by reinfection. Prophylaxis has dramatically lowered the rate of reinfection and increased patient survival. Long-term treatment with hepatitis B immunoglobulin (HBIg), although expensive, is effective. New antiviral nucleoside analogs have also been evaluated. In patients with cirrhosis and replicative HBV infection, lamivudine before transplantation and in combination with HBIg post transplantation reduces reinfection, but the rate of resistance mutation is rather high, reaching 25% at 2 years. Adefovir has been used as a rescue therapy and prior to transplantation in lamivudine-resistant patients, significantly improving liver function and reducing HBV DNA levels. Patients with active viral replication should receive preoperative antiviral therapy with lamivudine. HBIg therapy may be discontinued in selected patients after transplantation, albeit with caution, because low levels of HBV DNA have persisted. Antiviral therapy has improved the prognosis after graft infection.

Orthotopic liver transplantation - reinfection - antiviral therapy - resistance mutation

REFERENCES

• 1 European Liver Transplant Registry-ELTR .Registry for the European Liver Transplant Association. Data analysis, 05/1968-06/2002. Available at: www.eltr.org. Accessed on November 20, 2003
• 2 O'Grady J G, Smith H M, Davies S E et al.. Hepatitis B virus re-infection after orthotopic liver transplantation. Serological and clinical implications.  J Hepatol. 1992;  14 104-111
• 3 Steinmuller T, Seehofer D, Rayes N et al.. Increasing applicability of liver transplantation for patients with hepatitis B-related liver disease.  Hepatology. 2002;  35 1528-1535
• 4 Shouval D, Samuel D. Hepatitis B immune globulin to prevent HBV graft reinfection following liver transplantation: a concise review.  Hepatology. 2000;  32 1189-1195
• 5 Samuel D, Muller R, Alexander G et al.. Liver transplantation in European patients with the hepatitis B surface antigen.  N Engl J Med. 1993;  329 1842-1847
• 6 Samuel D, Bismuth A, Mathieu D et al.. Passive immunoprophylaxis after liver transplantation in HBsAg-positive patients.  Lancet. 1991;  337 813-815
• 7 Lauchart W, Muller R, Pichlmayr R. Long-term immunoprophylaxis of hepatitis B virus (HBV) re-infection in recipients of human liver allografts.  Transpl Proc. 1987;  19 4051-4053
• 8 Roche B, Feray C, Gigou M et al.. HBV DNA persistence 10 years after liver transplantation despite successful anti-HBs immunoprophylaxis.  Hepatology. 2003;  38 86-95
• 9 Terrault N A, Zhou S, Combs C et al.. Prophylaxis in liver transplant recipients using a fixed dosing schedule of hepatitis B immunoglobulins.  Hepatology. 1996;  24 1327-1333
• 10 Muller R, Gubernatis G, Farle M et al.. Liver transplantation in HBs antigen (HBsAg) carriers. Prevention of hepatitis B virus (HBV) recurrence by passive immunization.  J Hepatol. 1991;  13 90-96
• 11 Han S H, Martin P, Edelstein M et al.. Conversion from intravenous to intramuscular hepatitis B immune globulin in combination with lamivudine is safe and cost-effective in patients receiving long-term prophylaxis to prevent hepatitis B recurrence after liver transplantation.  Liver Transpl. 2003;  9 182-187
• 12 McGory R W, Ishitani M B, Oliveira W M et al.. Improved outcome of orthotopic liver transplantation for chronic hepatitis B cirrhosis with aggressive passive immunization.  Transplantation. 1996;  61 1358-1364
• 13 Lowell J A, Burgess S, Shenoy S et al.. Mercury poisoning associated with high-dose hepatitis-B immune globulin administration after liver transplantation for chronic hepatitis B.  Liver Transpl Surg. 1996;  2 475-478
• 14 Ghany M G, Ayola B, Villamil F G et al.. Hepatitis B virus S mutants in liver transplant recipients who were reinfected despite hepatitis B immune globulin prophylaxis.  Hepatology. 1998;  27 213-222
• 15 Terrault N A, Zhou S, McGory R W et al.. Incidence and clinical consequences of surface and polymerase gene mutations in liver transplant recipients on hepatitis B immunoglobulin.  Hepatology. 1998;  28 555-561
• 16 Brind A, Jiang J J, Samuel D et al.. Evidence for selection of hepatitis B mutants after liver transplantation through peripheral blood mononuclear cell infection.  J Hepatol. 1997;  26 228-235
• 17 Villeneuve J P, Condreay L D, Willems B et al.. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B.  Hepatology. 2000;  31 207-210
• 18 Kapoor D, Guptan R C, Wakil S M et al.. Beneficial effects of lamivudine in hepatitis B virus-related decompensated cirrhosis.  J Hepatol. 2000;  33 308-312
• 19 Perrillo R P, Wright T, Rakela J et al.. A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after transplantation for chronic hepatitis B.  Hepatology. 2001;  33 424-432
• 20 Fontana R, Keeffe E, Carey W et al.. Effect of lamivudine treatment on survival of 309 North American patients awaiting liver transplantation for chronic hepatitis B.  Liver Transpl. 2002;  8 433-439
• 21 Perrillo R, Schiff E, Yoshida E et al.. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants.  Hepatology. 2000;  32 129-134
• 22 Stärkel P, Horsmans Y, Geubel A et al.. Favorable outcome of orthotopic liver transplantation in a patient with subacute liver failure due to emergence of a hepatitis B YMDD escape mutant virus.  J Hepatol. 2001;  35 679-681
• 23 Saab S, Kim M, Wright T et al.. Successful orthotopic liver transplantation for lamivudine associated YMDD mutant hepatitis B virus.  Gastroenterology. 2000;  119 1382-1384
• 24 Rosenau J, Bahr M, Tillmann H L et al.. Lamivudine and low-dose hepatitis B immune globulin for prophylaxis of hepatitis B reinfection after liver transplantation. Possible role of mutations in the YMDD motif prior to transplantation as a risk factor for reinfection.  J Hepatol. 2001;  34 895-902
• 25 Grellier L, Mutimer D, Ahmed M et al.. Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis.  Lancet. 1996;  348 1212-1215
• 26 Mutimer D, Dusheiko G, Barrett C et al.. Lamivudine without HBIg for prevention of graft reinfection by hepatitis B: long-term follow-up.  Transplantation. 2000;  70 809-815
• 27 Schiff E, Lai C L, Hadziannis S et al.. Adefovir dipivoxil therapy for lamivudine resistant hepatitis B in pre- and post-liver transplantation patients.  Hepatology. 2003;  38 1419-1427
• 28 Markowitz J S, Martin P, Conrad A J et al.. Prophylaxis against hepatitis B recurrence following liver transplantation using combination Lamivudine and hepatitis B immune globulin.  Hepatology. 1998;  28 585-589
• 29 Marzano A, Salizzoni M, Debernardi-Venon W et al.. Prevention of hepatitis B virus recurrence after liver transplantation in cirrhotic patients treated with Lamivudine and passive immunoprophylaxis.  J Hepatol. 2001;  34 903-910
• 30 Angus P W, McCaughan G W, Gane E J et al.. Combination low-dose hepatitis B immune globulin and lamivudine therapy provides effective prophylaxis against posttransplantation hepatitis B.  Liver Transpl. 2000;  6 429-433
• 31 Sanchez-Fueyo A, Rimola A, Grande L et al.. Hepatitis B immunoglobulin discontinuation followed by hepatitis B virus vaccination: a new strategy in the prophylaxis of hepatitis B virus recurrence after liver transplantation.  Hepatology. 2000;  31 496-501
• 32 Sanchez-Fueyo A, Martinez-Bauer E, Rimola A. Hepatitis B vaccination after liver transplantation.  Hepatology. 2002;  36 257-258
• 33 Bienzle U, Gunther M, Neuhaus R et al.. Immunization with an adjuvant hepatitis B vaccine after liver transplantation for hepatitis B virus-related disease.  Hepatology. 2003;  38 811-819
• 34 Angelico M, Di Paolo D, Trinito M et al.. Failure of a reinforced triple course of hepatitis B vaccination in patients transplanted for HBV-related cirrhosis.  Hepatology. 2002;  35 176-181
• 35 Dodson S F, De Vera M E, Bonham C A et al.. Lamivudine after hepatitis B immune globulin is effective in preventing hepatitis B recurrence after liver transplantation.  Liver Transpl. 2000;  6 434-439
• 36 Naoumov N V, Lopes A R, Burra P et al.. Randomized trial of lamivudine versus hepatitis B immunoglobulin for long-term prophylaxis of hepatitis B recurrence after liver transplantation.  J Hepatol. 2001;  34 888-894
• 37 Buti M, Mas A, Prieto M et al.. A randomized study comparing lamivudine monotherapy after a short course of hepatitis B immune globulin (HBIg) and lamivudine with long-term lamivudine plus HBIg in the prevention of hepatitis B virus recurrence after liver transplantation.  J Hepatol. 2003;  38 811-817
• 38 Terrault N A, Holland C C, Ferrell L et al.. Interferon alfa for recurrent hepatitis B infection after liver transplantation.  Liver Transpl Surg. 1996;  2 132-138
• 39 Roche B, Samuel D, Gigou M et al.. Long-term ganciclovir therapy for hepatitis B virus infection after liver transplantation.  J Hepatol. 1999;  31 584-592
• 40 Perrillo R, Rakela J, Dienstag J et al.. Multicenter study of lamivudine therapy for hepatitis B after liver transplantation.  Hepatology. 1999;  29 1581-1586
• 41 Fontana R J, Hann H W, Wright T et al.. A multicenter study of lamivudine treatment in 33 patients with hepatitis B after liver transplantation.  Liver Transpl. 2001;  7 504-510
• 42 Bock C T, Tillmann H L, Torresi J et al.. Selection of hepatitis B virus polymerase mutants with enhanced replication by lamivudine treatment after liver transplantation.  Gastroenterology. 2002;  122 264-273
• 43 Walsh K M, Woodall T, Lamy P et al.. Successful treatment with adefovir dipivoxil in a patient with fibrosing cholestatic hepatitis and lamivudine resistant hepatitis B virus.  Gut. 2001;  49 436-440
• 44 Yang H, Westland C E, Delaney W E et al.. Resistance surveillance in chronic hepatitis B patients treated with adefovir dipivoxil for up to 60 weeks.  Hepatology. 2002;  36 464-473
• 45 Crippin J, Foster B, Carlen S et al.. Retransplantation in hepatitis B-a multicenter experience.  Transplantation. 1994;  57 823-826
• 46 Roche B, Samuel D, Feray C et al.. Retransplantation of the liver for recurrent hepatitis B virus infection: the Paul Brousse experience.  Liver Transpl Surg. 1999;  5 166-174